Neuralstem Inc

Find Ratings Reports
CUR : NASDAQ : Health Care
$4.55 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 167900.0
05/22/17 - 4:00 PM ET

Financial Analysis


NEURALSTEM INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. NEURALSTEM INC is extremely liquid. Currently, the Quick Ratio is 2.76 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 128.12% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)0.010.0
EBITDA ($mil)-5.12-4.26
EBIT ($mil)-5.18-4.35
Net Income ($mil)-5.4-4.77


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)20.212.23
Total Assets ($mil)22.615.05
Total Debt ($mil)3.718.03
Equity ($mil)11.334.97


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin-64000.0-213100.0
EBITDA Margin-64000.0-213100.0
Operating Margin-64787.5-217600.0
Sales Turnover0.00.0
Return on Assets-93.23-138.91
Return on Equity-185.99-420.85
Debt Q4 FY16 Q4 FY15
Current Ratio2.852.08
Debt/Capital0.250.62
Interest Expense0.190.44
Interest Coverage-27.14-9.91


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)11.037.08
Div / share0.00.0
EPS-0.52-0.65
Book value / share1.030.7
Institutional Own % n/a n/a
Avg Daily Volume172871.0560961.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 4.55 indicates a significant premium versus the S&P 500 average of 3.00 and a significant discount versus the industry average of 9.84. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, NEURALSTEM INC seems to be trading at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CUR NM Peers 39.69   CUR NM Peers 41.03

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CUR's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CUR's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CUR NM Peers 23.10   CUR NA Peers 0.48

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

CUR's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CUR 4.55 Peers 9.84   CUR 13.05 Peers -13.13

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CUR is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

CUR is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CUR 2576.16 Peers 108.22   CUR 60.00 Peers 462.39

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CUR is trading at a significant premium to its industry.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

CUR significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades